Kendle enters into new $35M secured revolving credit facility with JPMorgan Chase Bank N.A.

Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced that it has entered into a new $35 million secured revolving credit facility as of March 15, 2010 with JPMorgan Chase Bank N.A., as administrative agent, which replaces the Company's previous revolving credit facility. The new facility contains provisions allowing the Company to request an increase of up to $15 million in capacity, subject to the consent of the current lender or additional lenders.  The new revolving facility matures on January 15, 2012 and is automatically extended to March 31, 2015 if certain conditions are met related to the Company's convertible notes.  

Commenting on the transaction, Keith Cheesman, Senior Vice President and Chief Financial Officer said, "We are very pleased with this new facility and with having JPMorgan Chase serve as our agent.  This new facility offers more flexible terms and conditions, together with a duration and a capacity, all of which will better position us to execute against our long-term strategic plans."

Under the terms of this new facility, the Company may borrow in U.S. dollars or other globally-traded currencies, including the Euro and the Pound Sterling. The new credit agreement contains various affirmative and negative covenants including limitations on capital expenditures, investments, indebtedness, acquisitions and asset sales outside the ordinary course of business.  The new agreement also contains various financial covenants including a total leverage ratio, a senior leverage ratio and an interest coverage ratio.  Additional details about the new credit facility are available in the Company's most recently filed Annual Report on Form 10-K.

Source:

Kendle International Inc.

Posted in:

Tags:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research explores how antimicrobial exposure affects Parkinson’s disease risk